Compare the three chromium formats head-to-head — the trial-dose picolinate standard, the niacin-bound GTF-heritage form, and the brewer's-yeast food-form original. In chromium's comparison, the honest principle is: the evidence, not the form, is the product — picolinate holds the trials, the heritage forms hold the stories, and the category as a whole holds a maybe.



| Metric | 🏆Chromium Picolinate 500 mcg Various (USP-grade chromium picolinate) | Chromium Polynicotinate 200 mcg Various (niacin-bound chromium) | Brewer's Yeast (GTF-Chromium Complex) Various (Saccharomyces cerevisiae) |
|---|---|---|---|
| Delivery Form | Tablet | Capsule | Tablet |
| Strength | 500 mcg elemental chromium (as picolinate) | 200 mcg elemental chromium (as polynicotinate) | GTF-chromium complex (~50 mcg per 2-tablet serving) |
| Servings / Container | 120 | 90 | 180 |
| Retail Price | $9.99 | $12.99 | $14.99 |
| Cost / Serving | $0.08BEST 💰 | $0.14 | $0.08 |
| Overall Score | 74/100 | 70/100 | 68/100 |
| 3rd-Party Testing | None | None | None |
| Vegan Friendly | ✓ Yes | ✓ Yes | ✓ Yes |
The adequate intake is a microgram nutritional estimate; the standard supplement dose is 15–20× that — a pharmacologic exposure sold in nutritional vocabulary. Both numbers belong on the label; only one ever appears there.
The strongest human evidence that chromium is necessary remains the 1977 TPN case and its handful of successors — all from artificial feeding, none from a healthy eater's diet. The AI-not-RDA status is not a technicality; it is the file.
The pooled weight effect the fat-burner era never survived: statistically detectable, clinically trivial, and formally retired alongside the FTC's 1990s actions. Buy it for the maybe-glycemic file or not at all — never for this.
Supplements are trivalent chromium — low-toxicity, poorly absorbed, the form of the entire nutritional literature. Hexavalent chromium is the industrial carcinogen of environmental disasters: a different molecule, never in a bottle. The conflation serves fear-marketers on both sides.
The 1997 China trial's dose-response HbA1c reductions have stood for nearly three decades without a comparable-scale confirmation — the single-anchor evidence shape that keeps the whole category at 'maybe.'
No tolerable upper intake is established — an absence of data, not proof of safety. The studied range is 200–1000 mcg; the renal case reports cluster above it; and the megadose blends are the kitchen-sink tier regardless.